(Also see "Sanofi Dives Back Into ADCs With Seagen Pact" - Scrip, 17 March, 2022.)	Despite underwhelming sales for some cancer products and problems within the pipeline, Sanofi is forging ahead with an agreement for up to three ADCs with Seagen.
(Also see "Akorn Sharpens Focus As It Divests Ophthalmic Brands" - Generics Bulletin, 15 March, 2022.)	Akorn says it is concentrating its focus on “targeted avenues of growth” – including human generics and animal care – after divesting its branded ophthalmic portfolio to Théa Pharma.
(Also see "Sanofi Challenges J&J’s Darzalex With Blackstone Pact For SC Sarclisa" - Scrip, 15 March, 2022.)	Sanofi has entered a risk-sharing collaboration with Blackstone focused on a new formulation of multiple myeloma drug Sarclisa, which could help it take on market leader Darzalex.
(Also see "Sandoz Bolsters Respiratory Aspirations With Coalesce Acquisition" - Generics Bulletin, 14 March, 2022.)	Sandoz is targeting growth opportunities in the respiratory complex generics space with the acquisition of UK-based drug delivery device firm Coalesce.
(Also see "Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement" - Scrip, 15 March, 2022.)	Biogen and Eisai amended the terms of their Alzheimer’s collaboration to give Biogen full decision-making control over Aduhelm immediately. Eisai’s 50% share of profits and losses from the drug switches to a 2% royalty in 2023. The partners’ agreement for Eisai-led lecanemab remains intact.
(Also see "Hikma Has An Appetite For More Deals As It Builds On Acquisitions" - Generics Bulletin, 10 March, 2022.)	Hikma has the financial firepower and appetite to maintain its current deal-making momentum following several key transactions over the past year, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview, while also detailing how the firm plans to build up its US biosimilars business.
(Also see "Neuraxpharm’s Brain Acquisition Stems From Expansion Ambitions" - Generics Bulletin, 10 March, 2022.)	Privately owned Neuraxpharm has found another company to give it further access to a new European market, picking up Athens-based Brain Therapeutics. It aims now to introduce its Buccolam (midazolam) in Greece.
(Also see "Novartis Bets Big On Next-Gen Gene Therapy With Voyager Pact" - Scrip, 8 March, 2022.)	Novartis has gained access to next-generation AAV capsids that could reach cells in the brain, something that has not been possible with technologies used to date.
(Also see "Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership" - Generics Bulletin, 8 March, 2022.)	Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.
(Also see "Who Were Big Pharma's Top Deal-Makers In 2021?" - Scrip, 4 March, 2022.)	INFOGRAPHIC: Roche/Genentech was the busiest deal-maker in big pharma for second consecutive year in 2021, followed by Sanofi, Takeda, Lilly, Novartis and Pfizer.
(Also see "Merck KGaA Keeps Powder Dry On Licensing Deals" - Scrip, 3 March, 2022.)	After doing a number of health care deals in 2021, it looks as though Merck KGaA will keep M&A activity to a minimum for the division this year, focusing instead on advancing its own promising candidates for cancer, multiple sclerosis and lupus.
(Also see "Henlius Partners With Getz To Commercialize Adalimumab Biosimilar" - Generics Bulletin, 3 March, 2022.)	Henlius and Getz Pharma have partnered to commercialize Henlius’ adalimumab biosimilar in 11 emerging markets in Asia, Africa and Europe.
(Also see "Ipsen Seeks Success Outside Big Pharma's Hunting Grounds" - Scrip, 2 March, 2022.)	David Loew has assembled a strong business development team which secured seven licensing pacts in 2021 and the Ipsen CEO tells Scrip that this year should see more of the same.
(Also see "Sanofi Will Employ Adagene’s Technology For Precision Targeting In Cancer" - Scrip, 2 March, 2022.)	Sanofi will pay $17.5m up front to license candidates developed with Adagene’s SAFEbody platform, which can mask antibodies, enabling them to reach cancer targets in the tumor microenvironment.
(Also see "Rallybio Looks To Deals To Grow ‘Transformative’ Rare Disease Pipeline" - Scrip, 2 March, 2022.)	Armed with the insight of its ex-Alexion leaders, Rallybio is eyeing a spate of deals to develop and commercialize transformative drugs for rare diseases.

Deal Watch: AbbVie Partners With Gedeon Richter In Neuropsychiatry

More from Deal Watch

More from Deals